(Q33803406)

29 July 2017

Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer (English)

1 reference

29 July 2017

1 reference

Filippo Montemurro

4

1 reference

ORCID Public Data File 2021

author name string

Caterina Peraldo-Neia

1

1 reference

29 July 2017

Giorgia Migliardi

2

1 reference

29 July 2017

Maurizia Mello-Grand

3

1 reference

29 July 2017

Raffaella Segir

5

1 reference

29 July 2017

Ymera Pignochino

6

1 reference

29 July 2017

Giuliana Cavalloni

7

1 reference

29 July 2017

Bruno Torchio

8

1 reference

29 July 2017

Luciano Mosso

9

1 reference

29 July 2017

Giovanna Chiorino

10

1 reference

29 July 2017

Massimo Aglietta

11

1 reference

29 July 2017

language of work or name

English

0 references

publication date

25 January 2011

1 reference

29 July 2017

1 reference

29 July 2017

11

1 reference

29 July 2017

31

1 reference

describes a project that uses

29 July 2017

limma

object named as

Limma

2 references

22 June 2022

https://europepmc.org/article/PMC/3040720

inferred from PubMed Central ID database lookup

CZ Software Mentions: A large dataset of software mentions in the biomedical literature

exact match

https://scigraph.springernature.com/pub.10.1186/1471-2407-11-31

0 references

cites work

A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3040720

Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3040720

Androgen receptor controls EGFR and ERBB2 gene expression at different levels in prostate cancer cell lines

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3040720

Gene expression of forkhead transcription factors in the normal and diseased human prostate

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3040720

Androgen regulation of multidrug resistance-associated protein 4 (MRP4/ABCC4) in prostate cancer

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3040720

Expression and prognostic relevance of annexin A3 in prostate cancer

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3040720

Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3040720

Reduced expression and tumor suppressor function of the ETS transcription factor ESE-3 in prostate cancer

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3040720

Involvement of epidermal growth factor receptor and downstream molecules in bone and soft tissue tumors

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3040720

Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3040720

Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3040720

Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3040720

Erlotinib in lung cancer - molecular and clinical predictors of outcome

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3040720

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3040720

20-year outcomes following conservative management of clinically localized prostate cancer

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3040720

Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3040720

Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3040720

Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3040720

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3040720

4 July 2018

Cancer statistics, 2004

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3040720

Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3040720

Suppression of prostate tumor growth by U19, a novel testosterone-regulated apoptosis inducer

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3040720

Phase I studies of ZD1839 in patients with common solid tumors

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3040720

The involvement of human-nuc gene in polyploidization of K562 cell line.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3040720

Dysregulated expression of growth factors and their receptors in the development of prostate cancer

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3040720

Epidermal growth factor receptor (ErbB1) expression in prostate cancer progression: correlation with androgen independence.

4 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-31

Prednisone plus gefitinib versus prednisone plus placebo in the treatment of hormone-refractory prostate cancer: a randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-31

[Pharmacokinetic MRI of the prostate: parameters for differentiating low-grade and high-grade prostate cancer].

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-31

Definition of biochemical recurrence after radical prostatectomy does not substantially impact prognostic factor estimates

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-31

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-31

An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-31

A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-31

Molecular alterations of EGFR and PTEN in prostate cancer: association with high-grade and advanced-stage carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-31

Novel mutations of epidermal growth factor receptor in localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-31

Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3040720

Racial Disparity of Epidermal Growth Factor Receptor Expression in Prostate Cancer

30 October 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-31

The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma

21 January 2018

1 reference

12 December 2020

Prostate cancer chemotherapy: emerging from the shadows

1 reference

12 December 2020

Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer

1 reference

12 December 2020

Prostate cancer epidemiology

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2407-11-31

1 reference

Dimensions Publication ID

29 July 2017

0 references

1 reference

29 July 2017

1 reference